Home > Insider Trading > Filing (0001104659-16-153349)

Filing Details

Accession Number:: 0001104659-16-153349
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-10-31 16:51:59
Reporting Period:: 2016-10-31

Filing Date:: 2016-10-31
Accepted Time:: 2016-10-31 16:51:59
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1481512	Ra Pharmaceuticals Inc.	RARX	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1439101	Morgenthaler Venture Partners Ix Lp	3200 Alpine Road Portola Valley CA 94028		No	No	Yes	No
1666860	Morgenthaler Management Partners Ix, Llc	3200 Alpine Road Portola Valley CA 94028		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-10-31	63,019	$0.07	80,161	No	4	X	Direct
Common Stock	Disposition	2016-10-31	340	$13.00	79,821	No	4	S	Direct
Common Stock	Acquisiton	2016-10-31	1,392,130	$0.00	1,471,951	No	4	C	Direct
Common Stock	Acquisiton	2016-10-31	523,438	$0.00	1,995,389	No	4	C	Direct
Common Stock	Acquisiton	2016-10-31	486,919	$0.00	2,482,308	No	4	C	Direct
Common Stock	Acquisiton	2016-10-31	263,538	$13.00	2,745,846	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	X	Direct
No	4	S	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants to Purchase Common Stock	Disposition	2016-10-31	63,019	$0.00	63,019	$0.07
Common Stock	Series A Preferred Stock	Disposition	2016-10-31	9,744,916	$0.00	1,392,130	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2016-10-31	3,664,071	$0.00	523,438	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2016-10-31	3,408,439	$0.00	486,919	$0.00

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2022-04-01	No	4	X	Direct
	No	4	C	Direct
	No	4	C	Direct
	No	4	C	Direct

Footnotes

The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. MMP IX disclaims beneficial ownership of the securities held by MVP IX except to the extent of its pecuniary interest therein.
The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares.
Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.
Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.
Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.